8-K: Palatin Technologies Announces 1-for-50 Reverse Stock Split

Palatin Technologies, Inc. will implement a 1-for-50 reverse stock split effective August 8, 2025, to address its low share price and NYSE American listing compliance issues.

Summary

• Palatin Technologies, Inc. filed a certificate of amendment to its Restated Certificate of Incorporation on August 6, 2025, to effectuate a 1-for-50 reverse stock split of its common stock.
• The reverse stock split will become effective on August 8, 2025, at 5:00 p.m., Eastern Time.
• Common stock is expected to begin trading on the OTCQB Market of the OTC Markets on a reverse stock split-adjusted basis on August 11, 2025, at market open.
• The company's ticker symbol on the OTCQB will temporarily be PTNTD for 20 trading days, including the effective date.
• Every 50 shares of issued and outstanding common stock will be combined into one share.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the average closing price for the five trading days immediately preceding August 8, 2025.
• The primary goal of the reverse stock split is to increase the per-share market price to satisfy NYSE American's listing qualifications, from which the company was delisted due to low selling price.
• Trading of the company's common stock was suspended on NYSE American on May 7, 2025, and it has since traded on the Pink Market (May 8, 2025, through June 6, 2025) and then the OTCQB Market (since June 9, 2025).

Sentiment

Score: 3

Explanation: The sentiment is negative due to the underlying reason for the reverse stock split (delisting from NYSE American due to low share price). While the action itself is a step towards compliance, it reflects past poor performance and does not inherently improve the company's operational or financial standing.

Positives

• The reverse stock split aims to increase the per-share market price, which is a necessary step to potentially regain compliance with exchange listing standards.
• Stockholders approved the reverse stock split, indicating alignment with the board's strategy to address listing issues.

Negatives

• The company was delisted from NYSE American on May 7, 2025, due to the low selling price of its common stock, indicating significant share price depreciation.
• The necessity of a reverse stock split often signals underlying challenges with a company's valuation or investor confidence.

Risks

• The company's common stock has a low selling price, which led to its delisting from NYSE American.
• There is no guarantee that the reverse stock split will enable the company to satisfy future listing qualifications or improve investor perception long-term.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects its common stock to begin trading on the OTCQB Market on a reverse stock split-adjusted basis on August 11, 2025. The primary objective of this action is to increase the per-share market price to satisfy NYSE American's listing qualifications, implying a future goal of potential relisting or improved market perception.

Management Comments

• The company's board of directors was granted authority by stockholders to determine the exact split ratio and when to proceed with the Reverse Stock Split.

Industry Context

Palatin Technologies operates in the biopharmaceutical industry, developing medicines based on melanocortin receptor systems. Companies in this sector, particularly those in development stages, can experience significant share price volatility and may undertake corporate actions like reverse stock splits to maintain market viability or exchange listing, especially if their products are not yet generating substantial revenue.

Comparison to Industry Standards

• The delisting from a major exchange like NYSE American due to low share price is a significant negative event, often seen in smaller biopharmaceutical companies struggling with clinical trial outcomes, funding, or market acceptance.
• Reverse stock splits are a common mechanism used by companies, including those in the biotech sector, to meet minimum bid price requirements for exchanges, but they do not inherently address the underlying business fundamentals or operational performance that led to the low share price.
• While the filing does not provide specific comparable companies, similar actions have been taken by other micro-cap or small-cap biopharmaceutical firms that have faced challenges in maintaining exchange listing standards, such as those that have experienced setbacks in drug development or commercialization.

Corporate Governance

Stakeholder Impact

• Shareholders will own fewer shares, but each share will have a proportionally higher price, aiming to improve market perception and liquidity.
• Stockholders who would otherwise receive fractional shares will receive cash payments, which may result in a small, non-equity payout for some investors.
• The action is intended to address listing compliance, which could potentially benefit shareholders by making the stock more attractive to a broader range of investors if it leads to relisting on a major exchange.

Next Steps

• Trading of common stock on the OTCQB Market on a Reverse Stock Split-adjusted basis is expected to begin on August 11, 2025.
• The company's ticker symbol will be PTNTD for 20 trading days following the effective date.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to address a compliance issue (delisting from NYSE American due to low share price). It does not fundamentally change the company's business operations, financial performance, or product pipeline. While it may temporarily increase the per-share price and potentially aid in future relisting efforts, it does not provide new information regarding growth drivers or improved profitability. Investors should hold to observe if the company can leverage this structural change to improve its underlying business and regain investor confidence, rather than making a decision solely based on this administrative action.

Keywords

Palatin Technologies, Reverse Stock Split, PTNT, OTCQB, NYSE American, Delisting, Biopharmaceutical, Corporate Action, Stock Price